Clinical TrialsThe number of active ADCs in NSCLC is small, and recent developments have been disappointing.
Drug EfficacyThe nivolumab combination cohort showed lower efficacy compared to the monotherapy cohort, likely due to the enrollment of more heavily pretreated patients.
Risk FactorsRisk factors for the stock include clinical, commercial, collaboration, dilution, and legal and intellectual property concerns.